COSM: Cosmos Health's Cana secures >25M-unit CMO orderbook; division positioned for >$10M/year profit

AI Summary

Cosmos Health (NASDAQ: COSM) says its wholly owned Cana Laboratories has secured a cumulative contract-manufacturing orderbook of more than 25 million units across multiple EU and international partners, with multi-year terms up to 10 years and orders spanning nine therapeutic categories. The company upgraded its 54,000 sq. ft. EU‑GMP/EMA‑certified Athens facility (~$5.5M capex) and added an ACG capsule-filling line; Cosmos says the CMO division is positioned to generate over $10 million in recurring annual profit at full capacity, while continuing to pursue additional contracts.

Positives

Cana secured a cumulative orderbook of >25 million units across multiple partners with terms up to 10 years
Manufacturing facility is EU‑GMP and EMA‑certified, recently upgraded with ~$5.5M investment and a new ACG capsule-filling line
Company projects the CMO division can generate >$10M in recurring annual profit at full capacity

Negatives

Profit projection depends on reaching full production capacity and realizing booked volumes
Some contracts are smaller or still under negotiation, leaving portions of the orderbook uncertain
Statements are forward-looking and subject to operational, market and regulatory risks that could affect realization